Mizuho Securities Remains a Buy on Atara Biotherapeutics (ATRA)

Mizuho Securities analyst Salim Syed maintained a Buy rating on Atara Biotherapeutics (ATRA) today and set a price target of $38.00. The company’s shares closed last Friday at $15.59.

According to TipRanks.com, Syed is a 1-star analyst with an average return of -3.8% and a 51.4% success rate. Syed covers the Healthcare sector, focusing on stocks such as Assembly Biosciences, Coherus Biosciences, and Unity Biotechnology.

Currently, the analyst consensus on Atara Biotherapeutics is a Strong Buy with an average price target of $33.25, an 119.8% upside from current levels. In a report issued on May 7, Canaccord Genuity also maintained a Buy rating on the stock with a $70.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $24.75 and a one-year low of $4.52. Currently, Atara Biotherapeutics has an average volume of 1.04M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Atara Biotherapeutics, Inc. operates as a clinical stage company, which engages in the development of novel therapeutics for patients with cancer, autoimmune, and viral diseases. Its pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in South San Francisco, CA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts